Medicare Enrolled

Dr. Rajan Saggar, MD

Pulmonary Disease · Los Angeles, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Consulting-driven
200 MEDICAL PLZ, Los Angeles, CA 90095
3108256654
In practice since 2006 (19 years)
NPI: 1255351854 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Saggar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Saggar? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Saggar

Dr. Rajan Saggar is a pulmonary disease specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Saggar performed 1,090 Medicare services across 312 unique beneficiaries.

Between the years covered by Open Payments, Dr. Saggar received a total of $382,108 from 19 pharmaceutical and/or device companies across 715 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Saggar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 34% volume in CA $382,108 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,090
Medicare services
Top 34% in CA for pulmonary disease
312
Unique beneficiaries
$122
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~57 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Critical care, first 30-74 min
Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient.
 378 $183 $1,800
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
 344 $102 $680
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
 328 $80 $858
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
 25 $110 $960
Exercise-induced lung stress test
A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising.
 15 $19 $429
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$382,108
Total received (2018-2024)
Avg $54,587/year across 7 years
Top 1% in CA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
19
Companies
715
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$192,195 (50.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$183,865 (48.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,048 (1.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$102,864
2023
$81,177
2022
$66,035
2021
$17,008
2020
$10,378
2019
$53,717
2018
$50,930

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
United Therapeutics Corporation
$53,866
Merck Sharp & Dohme LLC
$25,855
Actelion Pharmaceuticals US, Inc.
$16,455
Insmed, Inc.
$6,156
Bayer Healthcare Pharmaceuticals Inc.
$344
Alexion Pharmaceuticals, Inc.
$122
Johnson & Johnson Health Care Systems Inc.
$67
Top 3 companies account for 93.5% of 2024 payments
All-time payments by company (2018-2024) ›
United Therapeutics Corporation
$229,443
Actelion Pharmaceuticals US, Inc.
$69,504
Merck Sharp & Dohme LLC
$26,043
Boehringer Ingelheim Pharmaceuticals, Inc.
$13,721
Insmed, Inc.
$12,368
Bayer HealthCare Pharmaceuticals Inc.
$11,590
GlaxoSmithKline, LLC.
$8,202
La Jolla Pharmaceutical Company
$4,786
Genentech, Inc.
$4,256
Bayer Healthcare Pharmaceuticals Inc.
$747
Inari Medical, Inc.
$495
Genentech USA, Inc.
$263
Grifols USA, LLC
$179
Alexion Pharmaceuticals, Inc.
$122
Gilead Sciences, Inc.
$108
Janssen Pharmaceuticals, Inc
$104
Sandoz Inc.
$90
Johnson & Johnson Health Care Systems Inc.
$67
Abbott Laboratories
$20
Top 3 companies account for 85.1% of all-time payments
Associated products mentioned in payments ›
Adempas · All-In-One · DRAGONFLY OPSTAR · Esbriet · FLOWTRIEVER CATHETER · GIAPREZA · NONE · OFEV · OPSUMIT · ORENITRAM · Prolastin-C · REMODULIN · S · TREPROSTINIL · TYVASO · ULTOMIRIS · UPTRAVI · WINREVAIR · XARELTO · Xolair
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (50%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 1% for pulmonary disease in CA.

Looking for a pulmonary disease specialist in Los Angeles?
Compare pulmonary diseases in the Los Angeles area by procedure volume, costs, and industry payment transparency.
Browse pulmonary diseases nearby

Geographic Context

Pulmonary diseases within 10 mi
250
Per 100K population
2.5
County median income
$87,760
Nearest hospital
RONALD REAGAN UCLA MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data ✓ Medicare Util. Annual (CY lag)
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Saggar is a clinical cardiology specialist, with moderate Medicare volume, with consulting-driven industry engagement in the top 1% of CA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Saggar experienced with critical care, first 30-74 min?
Based on Medicare claims data, Dr. Saggar performed 378 critical care, first 30-74 min services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Saggar receive payments from pharmaceutical companies?
Yes. Dr. Saggar received a total of $382,108 from 19 companies across 715 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Saggar's costs compare to other pulmonary diseases in Los Angeles?
Dr. Saggar's average Medicare payment per service is $122. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Saggar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Los Angeles
Browse pulmonary diseases in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in CA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in CA
Which CA pulmonary diseases receive the most from drug and device companies.
By company
United Therapeutics Corporation Payments to Doctors
See all physicians who received payments from United Therapeutics Corporation.
By company
Actelion Pharmaceuticals US, Inc. Payments to Doctors
See all physicians who received payments from Actelion Pharmaceuticals US, Inc.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →